Literature DB >> 20488256

Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

Jennifer C Naylor1, Jason D Kilts, Christine M Hulette, David C Steffens, Dan G Blazer, John F Ervin, Jennifer L Strauss, Trina B Allen, Mark W Massing, Victoria M Payne, Nagy A Youssef, Lawrence J Shampine, Christine E Marx.   

Abstract

The neurosteroid allopregnanolone has pronounced neuroprotective actions, increases myelination, and enhances neurogenesis. Evidence suggests that allopregnanolone dysregulation may play a role in the pathophysiology of Alzheimer's disease (AD) and other neurodegenerative disorders. Our prior data demonstrate that allopregnanolone is reduced in prefrontal cortex in male patients with AD compared to male cognitively intact control subjects, and inversely correlated with neuropathological disease stage (Braak and Braak). We therefore determined if allopregnanolone levels are also reduced in AD patients compared to control subjects in temporal cortex, utilizing a larger set of samples from both male and female patients. In addition, we investigated if neurosteroids are altered in subjects who are APOE4 allele carriers. Allopregnanolone, dehydroepiandrosterone (DHEA), and pregnenolone levels were determined in temporal cortex postmortem samples by gas chromatography/mass spectrometry, preceded by high performance liquid chromatography (40 subjects with AD/41 cognitively intact control subjects). Allopregnanolone levels are reduced in temporal cortex in patients with AD (median 2.68 ng/g, n=40) compared to control subjects (median 5.64 ng/g, n=41), Mann-Whitney p=0.0002, and inversely correlated with Braak and Braak neuropathological disease stage (Spearman r=-0.38, p=0.0004). DHEA and pregnenolone are increased in patients with AD compared to control subjects. Patients carrying an APOE4 allele demonstrate reduced allopregnanolone levels in temporal cortex (Mann-Whitney p=0.04). In summary, our findings indicate that neurosteroids are altered in temporal cortex in patients with AD and related to neuropathological disease stage. In addition, the APOE4 allele is associated with reduced allopregnanolone levels. Neurosteroids may be relevant to the neurobiology and therapeutics of AD. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488256      PMCID: PMC2907131          DOI: 10.1016/j.bbalip.2010.05.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  99 in total

1.  Pregnenolone stabilizes microtubules and promotes zebrafish embryonic cell movement.

Authors:  Hwei-Jan Hsu; Ming-Ren Liang; Chao-Tsen Chen; Bon-chu Chung
Journal:  Nature       Date:  2006-01-26       Impact factor: 49.962

2.  Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse: implication of heterozygous NPC1 mutations being a risk for tauopathy.

Authors:  Wenxin Yu; Mihee Ko; Katsuhiko Yanagisawa; Makoto Michikawa
Journal:  J Biol Chem       Date:  2005-05-25       Impact factor: 5.157

3.  Replacement with GABAergic steroid precursors restores the acute ethanol withdrawal profile in adrenalectomy/gonadectomy mice.

Authors:  K R Kaufman; M A Tanchuck; M N Strong; D A Finn
Journal:  Neuroscience       Date:  2010-01-06       Impact factor: 3.590

4.  Apoptosis and in vitro Alzheimer disease neuronal models.

Authors:  P Calissano; C Matrone; G Amadoro
Journal:  Commun Integr Biol       Date:  2009

5.  In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine.

Authors:  Graziano Pinna; Erbo Dong; Kinzo Matsumoto; Erminio Costa; Alessandro Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

6.  Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.

Authors:  Elina Zotova; James Ar Nicoll; Raj Kalaria; Clive Holmes; Delphine Boche
Journal:  Alzheimers Res Ther       Date:  2010-01-22       Impact factor: 6.982

7.  Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors.

Authors:  R Bergeron; C de Montigny; G Debonnel
Journal:  J Neurosci       Date:  1996-02-01       Impact factor: 6.167

8.  Neurosteroids: Cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics.

Authors:  Sae-Bom Kim; Martin Hill; Yong-Tae Kwak; Richard Hampl; Do-Hyun Jo; Robert Morfin
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  Effects of antidepressant treatment on neuroactive steroids in major depression.

Authors:  E Romeo; A Ströhle; G Spalletta; F di Michele; B Hermann; F Holsboer; A Pasini; R Rupprecht
Journal:  Am J Psychiatry       Date:  1998-07       Impact factor: 18.112

10.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more
  28 in total

Review 1.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

2.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice.

Authors:  Chanpreet Singh; Lifei Liu; Jun Ming Wang; Ronald W Irwin; Jia Yao; Shuhua Chen; Sherry Henry; Richard F Thompson; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2011-07-30       Impact factor: 4.673

4.  Glycine and GABA(A) ultra-sensitive ethanol receptors as novel tools for alcohol and brain research.

Authors:  Anna Naito; Karan H Muchhala; Liana Asatryan; James R Trudell; Gregg E Homanics; Daya I Perkins; Daryl L Davies; Ronald L Alkana
Journal:  Mol Pharmacol       Date:  2014-09-22       Impact factor: 4.436

Review 5.  Sex and the development of Alzheimer's disease.

Authors:  Christian J Pike
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

6.  The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation.

Authors:  Subathra Murugan; Padmaja Jakka; Swapna Namani; Varadendra Mujumdar; Girish Radhakrishnan
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

Review 7.  Pregnenolone sulfate as a modulator of synaptic plasticity.

Authors:  Conor C Smith; Terrell T Gibbs; David H Farb
Journal:  Psychopharmacology (Berl)       Date:  2014-07-06       Impact factor: 4.530

8.  Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Authors:  Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

9.  Allopregnanolone attenuates Aβ25-35-induced neurotoxicity in PC12 cells by reducing oxidative stress.

Authors:  Xiaowei Qian; Hong Cao; Qian Ma; Qinsai Wang; Wei He; Peishun Qin; Bin Ji; Kaiming Yuan; Fanghua Yang; Xuhua Liu; Qingquan Lian; Jun Li
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 10.  Promising Intervention Approaches to Potentially Resolve Neuroinflammation And Steroid Hormones Alterations in Alzheimer's Disease and Its Neuropsychiatric Symptoms.

Authors:  Catia Scassellati; Antonio Carlo Galoforo; Ciro Esposito; Miriam Ciani; Giovanni Ricevuti; Cristian Bonvicini
Journal:  Aging Dis       Date:  2021-08-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.